Further, DTP-based retrieval of approved drugs showed that combination therapy with sorafenib, sunitinib, nintedanib (PDGFRB), sunitinib, nintedanib, ruxolitinib (JAK1), and ceritinib (IGF1R) could be helpful to diabetic COVID-19 patients. This evidence concerns the gene PDGFRB and COVID-19.